Can Zogenix, Inc. (ZGNX)’s Tomorrow be Different? The Stock Just Broke Its High

July 13, 2018 - By Russell Jones

Zogenix, Inc. (NASDAQ:ZGNX) Logo

The stock of Zogenix, Inc. (NASDAQ:ZGNX) hit a new 52-week high and has $63.45 target or 3.00 % above today’s $61.60 share price. The 6 months bullish chart indicates low risk for the $2.17B company. The 1-year high was reported on Jul, 13 by If the $63.45 price target is reached, the company will be worth $65.10 million more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock.

The stock increased 10.20% or $5.7 during the last trading session, reaching $61.6. About 2.86 million shares traded or 343.19% up from the average. Zogenix, Inc. (NASDAQ:ZGNX) has risen 225.58% since July 13, 2017 and is uptrending. It has outperformed by 213.01% the S&P500.

Analysts await Zogenix, Inc. (NASDAQ:ZGNX) to report earnings on August, 14. They expect $-0.90 EPS, 0.00 % or $0.00 from last year’s $-0.9 per share. After $-0.87 actual EPS reported by Zogenix, Inc. for the previous quarter, Wall Street now forecasts 3.45 % negative EPS growth.

More notable recent Zogenix, Inc. (NASDAQ:ZGNX) news were published by: which released: “Why Twitter, Papa John’s International, and Zogenix Jumped Today” on July 12, 2018, also with their article: “Broadcom Options Volume Explodes Amid Stock Sell-off” published on July 12, 2018, published: “Mid-Day Market Update: Crude Oil Down Over 1%; IZEA Shares Spike Higher” on July 12, 2018. More interesting news about Zogenix, Inc. (NASDAQ:ZGNX) were released by: and their article: “Pre-Open Movers 07/12: (ZGNX) (GLMD) (CA) Higher; (ZN) (ACRX) (AVGO) Lower (more…)” published on July 12, 2018 as well as‘s news article titled: “Zogenix Welcomes New Global Chief Commercial Officer” with publication date: July 02, 2018.

Zogenix, Inc., a pharmaceutical company, develops and commercializes therapies for the treatment of central nervous system disorders in the United States. The company has market cap of $2.17 billion. The companyÂ’s lead product candidate is the ZX008, a low-dose fenfluramine, which is in Phase III clinical trials for the treatment of seizures associated with Dravet syndrome. It currently has negative earnings. It also develops Relday, an injectable formulation of risperidone to treat the symptoms of schizophrenia and bipolar disorder in adults and teenagers with 13 years of age and older.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.